Disc Medicine (IRON) Stock Forecast & Price Target

Compare

535 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

IRON Analyst Ratings

Strong Buy

13 Buy

0 Hold

0 Sell

Based on 13 analysts giving stock ratings to

Disc

Medicine

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

IRON Stock 12 Month Forecast

Average Price Target

$121.10

▲(53.25% Upside)

Based on 13 Wall Street analysts offering 12 month price targets for Disc Medicine in the last 3 months. The average price target is $121.10 with a high forecast of $154.00 and a low forecast of $100.00. The average price target represents a 53.25% change from the last price of $79.02.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"46":"$46","155":"$155","73.25":"$73.3","100.5":"$100.5","127.75":"$127.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":154,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$154.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":121.1,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$121.10</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":100,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$100.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[46,73.25,100.5,127.75,155],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Apr<br/>2025","6":"Jul<br/>2025","9":"Oct<br/>2025","12":"Jan<br/>2026","25":"Jan<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,79.41,85.14769230769231,90.88538461538461,96.62307692307692,102.36076923076922,108.09846153846154,113.83615384615385,119.57384615384615,125.31153846153846,131.04923076923077,136.78692307692307,142.5246153846154,148.2623076923077,{"y":154,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,79.41,82.61692307692307,85.82384615384615,89.03076923076922,92.2376923076923,95.44461538461537,98.65153846153845,101.85846153846154,105.0653846153846,108.27230769230769,111.47923076923075,114.68615384615384,117.89307692307692,{"y":121.1,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,79.41,80.99384615384615,82.5776923076923,84.16153846153846,85.74538461538461,87.32923076923076,88.91307692307691,90.49692307692308,92.08076923076923,93.66461538461539,95.24846153846154,96.8323076923077,98.41615384615385,{"y":100,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":63.4,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":55.8,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":56.18,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":47.15,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":49.68,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":47.73,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":51.13,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":58.97,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":61.4,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":67.04,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":86.22,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":91.69,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":79.41,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$154.00

Average Price Target$121.10

Lowest Price Target$100.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Kristen Kluska

Cantor Fitzgerald

$153

Buy

93.62%

Upside

Reiterated

01/13/26

Cantor Fitzgerald Sticks to Their Buy Rating for Disc Medicine (IRON)

David Nierengarten

Wedbush

$110

Buy

39.21%

Upside

Reiterated

01/13/26

Wedbush Sticks to Their Buy Rating for Disc Medicine (IRON)

Martin Auster

Raymond James

$78.06→$117

Buy

48.06%

Upside

Reiterated

01/13/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Disc Medicine (NASDAQ: IRON), Nuvalent (NASDAQ: NUVL) and Roche Holding AG (Other OTC: RHHVF)

Evan Seigerman

BMO Capital

$120

Buy

51.86%

Upside

Reiterated

01/12/26

Maintaining a Buy on IRON: Confidence in Bitopertin’s Regulatory Path, Commercial Readiness, and Broader Hematology Pipeline Upside

Sean Laaman

Morgan Stanley

$115→$120

Buy

51.86%

Upside

Reiterated

01/08/26

Disc Medicine price target raised to $120 from $115 at Morgan StanleyDisc Medicine price target raised to $120 from $115 at Morgan Stanley

Danielle Brill

Truist Financial

Buy

―

Reiterated

12/22/25

Analysts Offer Insights on Healthcare Companies: BioNTech SE (NASDAQ: BNTX), Disc Medicine (NASDAQ: IRON) and Ascendis Pharma (NASDAQ: ASND)

Tara Bancroft

TD Cowen

Buy

―

Reiterated

12/19/25

TD Cowen says Disc Medicine remains confident, bito timeline under CNPV intactTD Cowen says Disc Medicine remains confident, bito timeline under CNPV intact

Stephen Willey

Stifel Nicolaus

Buy

―

Reiterated

12/19/25

Analysts Conflicted on These Healthcare Names: Moderna (NASDAQ: MRNA), Disc Medicine (NASDAQ: IRON) and Sagimet Biosciences, Inc. Class A (NASDAQ: SGMT)

Roger Song

Jefferies

$154

Buy

94.89%

Upside

Reiterated

12/19/25

Jefferies sees 'overreaction' to article on Disc Medicine's EPP approvabilityJefferies sees 'overreaction' to article on Disc Medicine's EPP approvability

Derek Archila

Wells Fargo

$91→$109

Buy

37.94%

Upside

Reiterated

12/16/25

Analysts Offer Insights on Healthcare Companies: SI-Bone (NASDAQ: SIBN), Disc Medicine (NASDAQ: IRON) and Novan (NASDAQ: NOVN)

Douglas Tsao

H.C. Wainwright

$118

Buy

49.33%

Upside

Reiterated

12/09/25

Disc Medicine's Promising Position in Anemia Treatment Boosts Buy Rating Amidst Competitor Setback

Rami Katkhuda

LifeSci Capital

$110

Buy

39.21%

Upside

Reiterated

12/07/25

Analysts' Top Healthcare Picks: Janux Therapeutics Inc (JANX), Disc Medicine (IRON)

Thomas Smith

Leerink Partners

$85→$100

Buy

26.55%

Upside

Reiterated

10/17/25

Leerink Partners Keeps Their Buy Rating on Disc Medicine (IRON)

Greg Harrison

Scotiabank

$75

Buy

-5.09%

Downside

Reiterated

06/17/25

Scotiabank Sticks to Their Buy Rating for Disc Medicine (IRON)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Kristen Kluska

Cantor Fitzgerald

$153

Buy

93.62%

Upside

Reiterated

01/13/26

Cantor Fitzgerald Sticks to Their Buy Rating for Disc Medicine (IRON)

David Nierengarten

Wedbush

$110

Buy

39.21%

Upside

Reiterated

01/13/26

Wedbush Sticks to Their Buy Rating for Disc Medicine (IRON)

Martin Auster

Raymond James

$78.06→$117

Buy

48.06%

Upside

Reiterated

01/13/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Disc Medicine (NASDAQ: IRON), Nuvalent (NASDAQ: NUVL) and Roche Holding AG (Other OTC: RHHVF)

Evan Seigerman

BMO Capital

$120

Buy

51.86%

Upside

Reiterated

01/12/26

Maintaining a Buy on IRON: Confidence in Bitopertin’s Regulatory Path, Commercial Readiness, and Broader Hematology Pipeline Upside

Sean Laaman

Morgan Stanley

$115→$120

Buy

51.86%

Upside

Reiterated

01/08/26

Disc Medicine price target raised to $120 from $115 at Morgan StanleyDisc Medicine price target raised to $120 from $115 at Morgan Stanley

Danielle Brill

Truist Financial

Buy

―

Reiterated

12/22/25

Analysts Offer Insights on Healthcare Companies: BioNTech SE (NASDAQ: BNTX), Disc Medicine (NASDAQ: IRON) and Ascendis Pharma (NASDAQ: ASND)

Tara Bancroft

TD Cowen

Buy

―

Reiterated

12/19/25

TD Cowen says Disc Medicine remains confident, bito timeline under CNPV intactTD Cowen says Disc Medicine remains confident, bito timeline under CNPV intact

Stephen Willey

Stifel Nicolaus

Buy

―

Reiterated

12/19/25

Analysts Conflicted on These Healthcare Names: Moderna (NASDAQ: MRNA), Disc Medicine (NASDAQ: IRON) and Sagimet Biosciences, Inc. Class A (NASDAQ: SGMT)

Roger Song

Jefferies

$154

Buy

94.89%

Upside

Reiterated

12/19/25

Jefferies sees 'overreaction' to article on Disc Medicine's EPP approvabilityJefferies sees 'overreaction' to article on Disc Medicine's EPP approvability

Derek Archila

Wells Fargo

$91→$109

Buy

37.94%

Upside

Reiterated

12/16/25

Analysts Offer Insights on Healthcare Companies: SI-Bone (NASDAQ: SIBN), Disc Medicine (NASDAQ: IRON) and Novan (NASDAQ: NOVN)

Douglas Tsao

H.C. Wainwright

$118

Buy

49.33%

Upside

Reiterated

12/09/25

Disc Medicine's Promising Position in Anemia Treatment Boosts Buy Rating Amidst Competitor Setback

Rami Katkhuda

LifeSci Capital

$110

Buy

39.21%

Upside

Reiterated

12/07/25

Analysts' Top Healthcare Picks: Janux Therapeutics Inc (JANX), Disc Medicine (IRON)

Thomas Smith

Leerink Partners

$85→$100

Buy

26.55%

Upside

Reiterated

10/17/25

Leerink Partners Keeps Their Buy Rating on Disc Medicine (IRON)

Greg Harrison

Scotiabank

$75

Buy

-5.09%

Downside

Reiterated

06/17/25

Scotiabank Sticks to Their Buy Rating for Disc Medicine (IRON)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Disc Medicine

3 Months

xxx

Success Rate

17/21 ratings generated profit

Average Return

+25.10%

reiterated a xxx

rating 3 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 80.95% of your transactions generating a profit, with an average return of +25.10% per trade.

1 Year

Thomas SmithLeerink Partners

Success Rate

17/21 ratings generated profit

Average Return

+34.55%

reiterated a buy rating 3 months ago

Copying Thomas Smith's trades and holding each position for 1 Year would result in 80.95% of your transactions generating a profit, with an average return of +34.55% per trade.

2 Years

xxx

Success Rate

21/21 ratings generated profit

Average Return

+64.45%

reiterated a xxx

rating 3 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +64.45% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

IRON Analyst Recommendation Trends

Rating

Sep 25

Oct 25

Nov 25

Dec 25

Jan 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, IRON has received 28 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. IRON average Analyst price target in the past 3 months is 121.10.

Each month's total comprises the sum of three months' worth of ratings.

IRON Financial Forecast

IRON Earnings Forecast

Next quarter’s earnings estimate for IRON is -$1.75 with a range of -$2.07 to -$1.51. The previous quarter’s EPS was -$1.77. IRON beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year IRON has Performed in-line its overall industry.

No data currently available

IRON Sales Forecast

Next quarter’s sales forecast for IRON is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. IRON beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year IRON has Performed in-line its overall industry.

IRON Stock Forecast FAQ

What is IRON’s average 12-month price target, according to analysts?

Based on analyst ratings, Disc Medicine’s 12-month average price target is 121.10.

What is IRON’s upside potential, based on the analysts’ average price target?

Disc Medicine has 53.25% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is IRON a Buy, Sell or Hold?

Disc Medicine has a consensus rating of Strong Buy which is based on 13 buy ratings, 0 hold ratings and 0 sell ratings.

What is Disc Medicine’s price target?

The average price target for Disc Medicine is 121.10. This is based on 13 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $154.00 ,the lowest forecast is $100.00. The average price target represents 53.25% Increase from the current price of $79.02.

What do analysts say about Disc Medicine?

Disc Medicine’s analyst rating consensus is a Strong Buy. This is based on the ratings of 13 Wall Streets Analysts.

How can I buy shares of IRON?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Disc Medicine (IRON) Stock Forecast & Price Target

IRON Analyst Ratings

IRON Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Disc Medicine

IRON Analyst Recommendation Trends

IRON Financial Forecast

IRON Earnings Forecast

IRON Sales Forecast

IRON Stock Forecast FAQ

Detailed List of Analyst Forecasts